Kenneth L. Waggoner
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Kenneth L. Waggoner
PharmaCyte Biotech, Inc. reported in an 8-K filed October 7, 2022 that Kenneth L. Waggoner resigned as President and General Counsel, effective October 6, 2022. PharmaCyte Biotech, Inc. reported in an 8-K filed October 7, 2022 that Kenneth L. Waggoner resigned as director on the Board of Directors, effective October 6, 2022. PharmaCyte Biotech, Inc. reported in an 8-K filed October 7, 2022 that Kenneth L. Waggoner resigned as Chief Executive Officer, effective October 6, 2022. The proxy statement of PharmaCyte Biotech, Inc. reports total compensation of $441,223 for Kenneth L. Waggoner in fiscal 2023, including a base salary of $433,334. Disclosed compensation is on record for 3 fiscal years.
“On October 6, 2022 (the "Separation Date"), Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech, Inc. (the "Company") resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the "Company Group") and as a director on the Board of Directors of the Company (the "Board").”
“On October 6, 2022 (the "Separation Date"), Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech, Inc. (the "Company") resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the "Company Group") and as a director on the Board of Directors of the Company (the "Board").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
PharmaCyte Biotech, Inc. (PMCB)
Proxy statement
Start not stated–2022-10-06
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | PharmaCyte Biotech, Inc. (PMCB) | Officer, President and General Counsel | $433,334 | $441,223 |
| 2022 | PharmaCyte Biotech, Inc. (PMCB) | Officer, President and General Counsel | $674,295 | $919,151 |
| 2021 | PharmaCyte Biotech, Inc. (PMCB) | — | $433,333 | $616,505 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.